{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:54:26Z","timestamp":1793040866774,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-24-1188643-01-IBCD"],"award-info":[{"award-number":["RSG-24-1188643-01-IBCD"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001287","name":"Elsa U. Pardee Foundation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100001287","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH2210262"],"award-info":[{"award-number":["W81XWH2210262"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R37CA269982"],"award-info":[{"award-number":["R37CA269982"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>CD16a triggers antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis by natural killer (NK) cells and macrophages in anti-tumor immunity. However, CD16a undergoes cleavage by ADAM17 that dampens its anti-tumor immunity. We here develop a monoclonal antibody (F9H4) that binds to CD16a and inhibits its cleavage. F9H4 retains CD16a on the surface of NK cells and macrophages, without triggering or blocking CD16a. F9H4 also binds to and inhibits shedding of CD16b by neutrophils, and inhibits CD16a\/b shedding by leukocytes in tumor samples from lung cancer patients. F9H4 promotes ADCC against lung cancer cells that are opsonized by cetuximab, an epidermal growth factor receptor antibody that engages CD16a. F9H4 synergizes with cetuximab to inhibit human lung adenocarcinoma development in immunodeficient mice reconstituted with human NK cells. F9H4 combining with cetuximab also inhibits murine lung carcinoma growth in Fc gamma receptor-humanized mice, and such effect is mediated by NK cells and macrophages. The efficacy of F9H4+cetuximab in lung cancer models is the proof-of-concept for this new approach that promotes anti-tumor functions of Fc-enabled antibodies.<\/jats:p>","DOI":"10.1038\/s41467-025-64862-5","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:32:40Z","timestamp":1762864360000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A monoclonal antibody that inhibits the shedding of CD16a and CD16b and promotes antibody-dependent cellular cytotoxicity against tumors"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2631-6719","authenticated-orcid":false,"given":"Bruna Taciane","family":"da Silva Bortoleti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Quasem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxuan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3423-5647","authenticated-orcid":false,"given":"Ruan","family":"Pimenta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1508-3817","authenticated-orcid":false,"given":"Luiza","family":"Ribeiro de Lima Brand\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Fraidenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Henrique","family":"Alves da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5404-1997","authenticated-orcid":false,"given":"Benjamin K.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2427-7843","authenticated-orcid":false,"given":"M\u00e1rcio Augusto","family":"Diniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Housman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja M.","family":"Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Brody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5903-8191","authenticated-orcid":false,"given":"Thomas U.","family":"Marron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2137-2271","authenticated-orcid":false,"given":"Lucas","family":"Ferrari de Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"64862_CR1","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1146\/annurev-immunol-051116-052433","volume":"35","author":"S Bournazos","year":"2017","unstructured":"Bournazos, S., Wang, T. T., Dahan, R., Maamary, J. & Ravetch, J. V. Signaling by antibodies: recent progress. Annu. Rev. Immunol. 35, 285\u2013311 (2017).","journal-title":"Annu. Rev. Immunol."},{"key":"64862_CR2","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1158\/1078-0432.CCR-06-1726","volume":"13","author":"J Kurai","year":"2007","unstructured":"Kurai, J. et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin. Cancer Res. 13, 1552\u20131561 (2007).","journal-title":"Clin. Cancer Res."},{"key":"64862_CR3","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1182\/blood-2012-04-425397","volume":"121","author":"R Romee","year":"2013","unstructured":"Romee, R. et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood 121, 3599\u20133608 (2013).","journal-title":"Blood"},{"key":"64862_CR4","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/eji.1830190431","volume":"19","author":"LL Lanier","year":"1989","unstructured":"Lanier, L. L., Phillips, J. H. & Testi, R. Membrane anchoring and spontaneous release of CD16 (FcR III) by natural killer cells and granulocytes. Eur. J. Immunol. 19, 775\u2013778 (1989).","journal-title":"Eur. J. Immunol."},{"key":"64862_CR5","doi-asserted-by":"publisher","first-page":"e0121788","DOI":"10.1371\/journal.pone.0121788","volume":"10","author":"Y Jing","year":"2015","unstructured":"Jing, Y. et al. Identification of an ADAM17 cleavage region in human CD16 (FcgammaRIII) and the engineering of a non-cleavable version of the receptor in NK cells. PLoS ONE 10, e0121788 (2015).","journal-title":"PLoS ONE"},{"key":"64862_CR6","doi-asserted-by":"publisher","first-page":"900","DOI":"10.4049\/jimmunol.152.2.900","volume":"152","author":"M de Haas","year":"1994","unstructured":"de Haas, M., Kleijer, M., Minchinton, R. M., Roos, D. & von dem Borne, A. E. Soluble Fc gamma RIIIa is present in plasma and is derived from natural killer cells. J. Immunol. 152, 900\u2013907 (1994).","journal-title":"J. Immunol."},{"key":"64862_CR7","first-page":"1911","volume":"30","author":"M Masuda","year":"2003","unstructured":"Masuda, M. et al. Increase of soluble FcgRIIIa derived from natural killer cells and macrophages in plasma from patients with rheumatoid arthritis. J. Rheumatol. 30, 1911\u20131917 (2003).","journal-title":"J. Rheumatol."},{"key":"64862_CR8","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00262-018-2193-1","volume":"67","author":"HK Mishra","year":"2018","unstructured":"Mishra, H. K., Pore, N., Michelotti, E. F. & Walcheck, B. Anti-ADAM17 monoclonal antibody MEDI3622 increases IFNgamma production by human NK cells in the presence of antibody-bound tumor cells. Cancer Immunol. Immunother. 67, 1407\u20131416 (2018).","journal-title":"Cancer Immunol. Immunother."},{"key":"64862_CR9","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ymthe.2019.10.009","volume":"28","author":"EJ Pomeroy","year":"2020","unstructured":"Pomeroy, E. J. et al. A genetically engineered primary human natural killer cell platform for cancer immunotherapy. Mol. Ther. 28, 52\u201363 (2020).","journal-title":"Mol. Ther."},{"key":"64862_CR10","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3109\/10409231003628015","volume":"45","author":"M Gooz","year":"2010","unstructured":"Gooz, M. ADAM-17: the enzyme that does it all. Crit. Rev. Biochem. Mol. Biol. 45, 146\u2013169 (2010).","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"64862_CR11","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1126\/science.282.5392.1281","volume":"282","author":"JJ Peschon","year":"1998","unstructured":"Peschon, J. J. et al. An essential role for ectodomain shedding in mammalian development. Science 282, 1281\u20131284 (1998).","journal-title":"Science"},{"key":"64862_CR12","doi-asserted-by":"publisher","first-page":"44151","DOI":"10.18632\/oncotarget.6629","volume":"6","author":"P Tsukerman","year":"2015","unstructured":"Tsukerman, P. et al. Cytokine secretion and NK cell activity in human ADAM17 deficiency. Oncotarget 6, 44151\u201344160 (2015).","journal-title":"Oncotarget"},{"key":"64862_CR13","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.humpath.2015.02.010","volume":"46","author":"RH Bandsma","year":"2015","unstructured":"Bandsma, R. H. et al. Loss of ADAM17 is associated with severe multiorgan dysfunction. Hum. Pathol. 46, 923\u2013928 (2015).","journal-title":"Hum. Pathol."},{"key":"64862_CR14","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa1100721","volume":"365","author":"DC Blaydon","year":"2011","unstructured":"Blaydon, D. C. et al. Inflammatory skin and bowel disease linked to ADAM17 deletion. N. Engl. J. Med. 365, 1502\u20131508 (2011).","journal-title":"N. Engl. J. Med."},{"key":"64862_CR15","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1158\/1078-0432.CCR-16-0869","volume":"23","author":"MA Miller","year":"2017","unstructured":"Miller, M. A., Sullivan, R. J. & Lauffenburger, D. A. Molecular pathways: receptor ectodomain shedding in treatment, resistance, and monitoring of cancer. Clin. Cancer Res. 23, 623\u2013629 (2017).","journal-title":"Clin. Cancer Res."},{"key":"64862_CR16","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1182\/blood.2019000621","volume":"135","author":"H Zhu","year":"2020","unstructured":"Zhu, H. et al. Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity. Blood 135, 399\u2013410 (2020).","journal-title":"Blood"},{"key":"64862_CR17","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1165\/ajrcmb\/5.4.307","volume":"5","author":"PC Levy","year":"1991","unstructured":"Levy, P. C. et al. Characterization of human alveolar macrophage Fc gamma receptor III: a transmembrane glycoprotein that is shed under in vitro culture conditions. Am. J. Respir. Cell Mol. Biol. 5, 307\u2013314 (1991).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"64862_CR18","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.bbamcr.2012.11.027","volume":"1833","author":"Y Wang","year":"2013","unstructured":"Wang, Y. et al. ADAM17 cleaves CD16b (FcgammaRIIIb) in human neutrophils. Biochim. Biophys. Acta 1833, 680\u2013685 (2013).","journal-title":"Biochim. Biophys. Acta"},{"key":"64862_CR19","doi-asserted-by":"publisher","first-page":"6591","DOI":"10.1074\/jbc.M009483200","volume":"276","author":"RL Shields","year":"2001","unstructured":"Shields, R. L. et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. 276, 6591\u20136604 (2001).","journal-title":"J. Biol. Chem."},{"key":"64862_CR20","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S1074-7613(00)00038-8","volume":"13","author":"Y Zhang","year":"2000","unstructured":"Zhang, Y. et al. Crystal structure of the extracellular domain of a human Fc gamma RIII. Immunity 13, 387\u2013395 (2000).","journal-title":"Immunity"},{"key":"64862_CR21","doi-asserted-by":"publisher","first-page":"16469","DOI":"10.1074\/jbc.M100350200","volume":"276","author":"S Radaev","year":"2001","unstructured":"Radaev, S., Motyka, S., Fridman, W. H., Sautes-Fridman, C. & Sun, P. D. The structure of a human type III Fcgamma receptor in complex with Fc. J. Biol. Chem. 276, 16469\u201316477 (2001).","journal-title":"J. Biol. Chem."},{"key":"64862_CR22","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1006\/cimm.1994.1268","volume":"158","author":"F Borrego","year":"1994","unstructured":"Borrego, F., Lopez-Beltran, A., Pena, J. & Solana, R. Downregulation of Fc gamma receptor IIIA alpha (CD16-II) on natural killer cells induced by anti-CD16 mAb is independent of protein tyrosine kinases and protein kinase C. Cell Immunol. 158, 208\u2013217 (1994).","journal-title":"Cell Immunol."},{"key":"64862_CR23","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/j.1365-3083.1989.tb01153.x","volume":"29","author":"CK Uggla","year":"1989","unstructured":"Uggla, C. K., Geisberg, M., Jondal, M. & Knowles, R. W. Agonistic effects of anti-CD2 and anti-CD16 antibodies on human natural killer killing. Scand. J. Immunol. 29, 507\u2013515 (1989).","journal-title":"Scand. J. Immunol."},{"key":"64862_CR24","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1002\/(SICI)1521-4141(199807)28:07<2101::AID-IMMU2101>3.0.CO;2-W","volume":"28","author":"J Galon","year":"1998","unstructured":"Galon, J. et al. Identification of the cleavage site involved in production of plasma soluble Fc gamma receptor type III (CD16). Eur. J. Immunol. 28, 2101\u20132107 (1998).","journal-title":"Eur. J. Immunol."},{"key":"64862_CR25","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1074\/mcp.RA119.001733","volume":"19","author":"JT Roberts","year":"2020","unstructured":"Roberts, J. T., Patel, K. R. & Barb, A. W. Site-specific N-glycan analysis of antibody-binding fc gamma receptors from primary human monocytes. Mol. Cell Proteom. 19, 362\u2013374 (2020).","journal-title":"Mol. Cell Proteom."},{"key":"64862_CR26","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1081\/IAS-120022940","volume":"24","author":"AS Belenky","year":"2003","unstructured":"Belenky, A. S., Wask-Rotter, E. & Sommer, M. J. Absence of protein G-Fc interaction in ficin-derived mouse IgG1 digests. J. Immunoass. Immunochem. 24, 311\u2013318 (2003).","journal-title":"J. Immunoass. Immunochem."},{"key":"64862_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17442-7","volume":"7","author":"I Katano","year":"2017","unstructured":"Katano, I. et al. Long-term maintenance of peripheral blood derived human NK cells in a novel human IL-15- transgenic NOG mouse. Sci. Rep. 7, 17230 (2017).","journal-title":"Sci. Rep."},{"key":"64862_CR28","doi-asserted-by":"publisher","first-page":"6181","DOI":"10.1073\/pnas.1203954109","volume":"109","author":"P Smith","year":"2012","unstructured":"Smith, P., DiLillo, D. J., Bournazos, S., Li, F. & Ravetch, J. V. Mouse model recapitulating human Fcgamma receptor structural and functional diversity. Proc. Natl. Acad. Sci. USA 109, 6181\u20136186 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"64862_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/0304-3835(80)90130-5","volume":"11","author":"JS Bertram","year":"1980","unstructured":"Bertram, J. S. & Janik, P. Establishment of a cloned line of Lewis lung carcinoma cells adapted to cell culture. Cancer Lett. 11, 63\u201373 (1980).","journal-title":"Cancer Lett."},{"key":"64862_CR30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/02841860701704724","volume":"47","author":"F Rivera","year":"2008","unstructured":"Rivera, F., Vega-Villegas, M. E., Lopez-Brea, M. F. & Marquez, R. Current situation of panitumumab, matuzumab, nimotuzumab and zalutumumab. Acta Oncol. 47, 9\u201319 (2008).","journal-title":"Acta Oncol."},{"key":"64862_CR31","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1080\/17425255.2018.1498839","volume":"14","author":"E Jimenez Aguilar","year":"2018","unstructured":"Jimenez Aguilar, E., Zugazagoitia Fraile, J. & Paz-Ares Rodriguez, L. Necitumumab: a new option for first-line treatment of squamous cell lung cancer. Expert Opin. Drug Metab. Toxicol. 14, 765\u2013772 (2018).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"64862_CR32","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S1470-2045(15)00021-2","volume":"16","author":"N Thatcher","year":"2015","unstructured":"Thatcher, N. et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol. 16, 763\u2013774 (2015).","journal-title":"Lancet Oncol."},{"key":"64862_CR33","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41586-020-2838-z","volume":"588","author":"S Bournazos","year":"2020","unstructured":"Bournazos, S., Corti, D., Virgin, H. W. & Ravetch, J. V. Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection. Nature 588, 485\u2013490 (2020).","journal-title":"Nature"},{"key":"64862_CR34","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1182\/blood.V90.3.1109","volume":"90","author":"HR Koene","year":"1997","unstructured":"Koene, H. R. et al. Fc gammaRIIIa-158V\/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L\/R\/H phenotype. Blood 90, 1109\u20131114 (1997).","journal-title":"Blood"},{"key":"64862_CR35","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1126\/science.aao0505","volume":"359","author":"L Ferrari de Andrade","year":"2018","unstructured":"Ferrari de Andrade, L. et al. Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity. Science 359, 1537\u20131542 (2018).","journal-title":"Science"},{"key":"64862_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.767697","volume":"11","author":"AR Templeton","year":"2021","unstructured":"Templeton, A. R. et al. Patient-derived explants as a precision medicine patient-proximal testing platform informing cancer management. Front. Oncol. 11, 767697 (2021).","journal-title":"Front. Oncol."},{"key":"64862_CR37","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1083\/jcb.201712085","volume":"217","author":"K Srpan","year":"2018","unstructured":"Srpan, K. et al. Shedding of CD16 disassembles the NK cell immune synapse and boosts serial engagement of target cells. J. Cell Biol. 217, 3267\u20133283 (2018).","journal-title":"J. Cell Biol."},{"key":"64862_CR38","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1002\/eji.200737266","volume":"37","author":"S Cecchetti","year":"2007","unstructured":"Cecchetti, S., Spadaro, F., Lugini, L., Podo, F. & Ramoni, C. Functional role of phosphatidylcholine-specific phospholipase C in regulating CD16 membrane expression in natural killer cells. Eur. J. Immunol. 37, 2912\u20132922 (2007).","journal-title":"Eur. J. Immunol."},{"key":"64862_CR39","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1158\/0008-5472.CAN-15-0781","volume":"75","author":"C Capuano","year":"2015","unstructured":"Capuano, C. et al. Anti-CD20 therapy acts via FcgammaRIIIA to diminish responsiveness of human natural killer cells. Cancer Res. 75, 4097\u20134108 (2015).","journal-title":"Cancer Res."},{"key":"64862_CR40","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/j.ccell.2021.10.009","volume":"39","author":"AM Leader","year":"2021","unstructured":"Leader, A. M. et al. Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification. Cancer Cell 39, 1594\u20131609 (2021).","journal-title":"Cancer Cell"},{"key":"64862_CR41","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.cell.2024.01.027","volume":"187","author":"F Petralia","year":"2024","unstructured":"Petralia, F. et al. Pan-cancer proteogenomics characterization of tumor immunity. Cell 187, 1255\u20131277.e1227 (2024).","journal-title":"Cell"},{"key":"64862_CR42","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.cell.2017.04.014","volume":"169","author":"Y Lavin","year":"2017","unstructured":"Lavin, Y. et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell 169, 750\u2013765 (2017).","journal-title":"Cell"},{"key":"64862_CR43","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41586-020-2422-6","volume":"583","author":"T Zhou","year":"2020","unstructured":"Zhou, T. et al. IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy. Nature 583, 609\u2013614 (2020).","journal-title":"Nature"},{"key":"64862_CR44","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2200568119","volume":"119","author":"NK Wolf","year":"2022","unstructured":"Wolf, N. K. et al. Synergy of a STING agonist and an IL-2 superkine in cancer immunotherapy against MHC I-deficient and MHC I(+) tumors. Proc. Natl. Acad. Sci. USA 119, e2200568119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"64862_CR45","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.exphem.2008.11.006","volume":"37","author":"M Shibata-Koyama","year":"2009","unstructured":"Shibata-Koyama, M. et al. Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcgammaRIIIb and MHC class II expression on the phagocytotic neutrophils. Exp. Hematol. 37, 309\u2013321 (2009).","journal-title":"Exp. Hematol."},{"key":"64862_CR46","doi-asserted-by":"publisher","first-page":"728","DOI":"10.4161\/mabs.28591","volume":"6","author":"U Reusch","year":"2014","unstructured":"Reusch, U. et al. A novel tetravalent bispecific TandAb (CD30\/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells. MAbs 6, 728\u2013739 (2014).","journal-title":"MAbs"},{"key":"64862_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105176","volume":"104","author":"JKM Wong","year":"2024","unstructured":"Wong, J. K. M. et al. TGF-beta signalling limits effector function capacity of NK cell anti-tumour immunity in human bladder cancer. EBioMedicine 104, 105176 (2024).","journal-title":"EBioMedicine"},{"key":"64862_CR48","first-page":"54","volume":"1","author":"R Pirker","year":"2012","unstructured":"Pirker, R. & Filipits, M. Cetuximab in non-small-cell lung cancer. Transl. Lung Cancer Res. 1, 54\u201360 (2012).","journal-title":"Transl. Lung Cancer Res."},{"key":"64862_CR49","doi-asserted-by":"publisher","first-page":"3798","DOI":"10.1200\/JCO.2003.11.069","volume":"21","author":"FR Hirsch","year":"2003","unstructured":"Hirsch, F. R. et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol. 21, 3798\u20133807 (2003).","journal-title":"J. Clin. Oncol."},{"key":"64862_CR50","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1182\/blood.V69.5.1307.1307","volume":"69","author":"ME Tweeddale","year":"1987","unstructured":"Tweeddale, M. E. et al. The presence of clonogenic cells in high-grade malignant lymphoma: a prognostic factor. Blood 69, 1307\u20131314 (1987).","journal-title":"Blood"},{"key":"64862_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmeth.2021.100080","volume":"1","author":"B Fitzgerald","year":"2021","unstructured":"Fitzgerald, B. et al. A mouse model for the study of anti-tumor T cell responses in Kras-driven lung adenocarcinoma. Cell Rep. Methods 1, 100080 (2021).","journal-title":"Cell Rep. Methods"},{"key":"64862_CR52","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1038\/sj.leu.2400768","volume":"11","author":"Y Matsuo","year":"1997","unstructured":"Matsuo, Y. et al. Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23). Leukemia 11, 1469\u20131477 (1997).","journal-title":"Leukemia"},{"key":"64862_CR53","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1182\/blood.2021011619","volume":"139","author":"PH Alves da Silva","year":"2022","unstructured":"Alves da Silva, P. H. et al. MICA\/B antibody induces macrophage-mediated immunity against acute myeloid leukemia. Blood 139, 205\u2013216 (2022).","journal-title":"Blood"},{"key":"64862_CR54","doi-asserted-by":"publisher","first-page":"e88226","DOI":"10.1172\/jci.insight.88226","volume":"2","author":"RA Alvarez","year":"2017","unstructured":"Alvarez, R. A. et al. Enhanced FCGR2A and FCGR3A signaling by HIV viremic controller IgG. JCI Insight 2, e88226 (2017).","journal-title":"JCI Insight"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64862-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64862-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64862-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T14:05:46Z","timestamp":1762869946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64862-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["64862"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-64862-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"23 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.F.d.A. and B.T.d.S.B. are named inventors in a patent that claimed F9H4 (WO2024026374A1) and filed by Mount Sinai Innovation Partners. L.F.d.A. is also named inventor in two patents that are related to 7C6 (WO2018217688A1 and WO2021072211A1) and filed through the Dana-Farber Cancer Institute; L.F.d.A. received royalty payments in relation to the antibody 7C6. L.F.d.A. also served as consultant in a translational advisory board for Cullinan MICA and has a consultancy agreement with Ono Pharmaceutical. All the other authors had no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9915"}}